Travis Partin, OD
Optometrist · Tulsa, OKNPI 1982181855
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $4,461 of the $5,691 with a category attached, or 78.4%. 23 manufacturers reported payments, led by Eyevance Pharmaceuticals LLC at 28.0% of the total. Reporting peaked in 2021 at $2,657 and has fallen 84.7% since, to $407 in 2025. Among optometrist clinicians in OK with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 152 payments — averaging $37.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Eyevance Pharmaceuticals LLC$2K
- Alcon$1K
- AbbVie$660
- Bausch & Lomb, A Division Of Bausch Health US, LLC$260
- Johnson & Johnson Vision Care, Inc.$258
- Oyster Point Pharma, Inc.$185
- plus $2K from 17 others
What the payments were for
- Consulting fees$301%
- Speaking & faculty fees$1,20021%
- Food & beverage$4,46178%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Eyevance Pharmaceuticals LLC | 7 | $1,596 |
| Alcon | 73 | $1,093 |
| AbbVie(2 entities) | 14 | $660 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 7 | $260 |
| Johnson & Johnson Vision Care, Inc. | 7 | $258 |
| Oyster Point Pharma, Inc. | 4 | $185 |
| Dompe US, Inc. | 4 | $175 |
| Kala Pharmaceuticals, Inc. | 6 | $175 |
| Optos, Inc. | 4 | $157 |
| The Cameron-ehlen Group, Inc. | 1 | $143 |
| Aerie Pharmaceuticals, Inc. | 2 | $140 |
| Sun Pharmaceutical Industries Inc. | 1 | $121 |
| Glaukos Corporation | 1 | $121 |
| Novartis | 2 | $119 |
| Harrow Eye, LLC | 5 | $111 |
| NEW World Medical,inc. | 1 | $103 |
| Tarsus Pharmaceuticals, Inc. | 3 | $65 |
| Sight Sciences, Inc. | 2 | $56 |
| Shire North American Group Inc | 3 | $44 |
| Staar Surgical Company | 1 | $31 |
| Coopervision Inc. | 2 | $29 |
| Rxsight Inc | 1 | $25 |
| Bausch & Lomb Americas Inc. | 1 | $23 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Zerviate$1,465
- Tecnis IOL$428
- PanOptix$252
- RESTASIS$243
- Precision 1$184
- HEALON PRO$143
- Tecnis Simplicity$143
- BIOTRUE$123
- ULTRA$123
- BIOTRUE ONE DAY$123
- Acuvue$122
- Rocklatan$121
- Rhopressa$121
- CEQUA$121
- iStent Trabecular Micro-Bypass Stent System$121
- iStent inject Trabecular Micro-Bypass Stent System$121
- Photrexa$121
- LUMIGAN$121
- EYSUVIS$118
- VUITY$116
How this compares
$5,691 in reported general payments places this provider in the 90th percentile of 714 optometrist providers in Oklahoma.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 25 | $23,362 |
| MieboPerfluorohexyloctane/Pf | 29 | $23,054 |
| XdemvyLotilaner | 12 | $22,747 |
| LumiganBimatoprost | 18 | $10,149 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 15 | $3,139 |
| Prednisolone Acetate | 64 | $1,860 |
| Brimonidine Tartrate | 13 | $1,580 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 32 | $1,472 |
| MoxifloxacinMoxifloxacin Hcl | 17 | $654 |
| Latanoprost | 35 | $463 |
| Timolol Maleate | 20 | $388 |
| Doxycycline Hyclate | 19 | $352 |
| ErythromycinErythromycin Base | 14 | $160 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan | $660 | $33,51143 claims |
| Bausch & Lomb Americas Inc.Miebo | $23 | $23,05429 claims |
| Tarsus Pharmaceuticals, Inc.Xdemvy | $65 | $22,74712 claims |
| AlconSimbrinza | $1,093 | $3,13915 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 714 optometrist providers in Oklahoma.
Other optometrist in Tulsa
- Lindsey BullTulsa$218K
- Wesley DerosierTulsa$48K
- Brian WilliamsTulsa$9K
- Lynsey BigheartTulsa$9K
- Shannon MorgansTulsa$8K
- Blane SnodgrassTulsa$7K
- Brett BeasleyTulsa$6K
- Christopher McDanielsTulsa$5K
- Terry LawsonTulsa$4K
- Selina McGeeEdmond$1.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.